Results 221 to 230 of about 152,141 (270)

Efficacy and Safety of Anal High‐Grade Squamous Intraepithelial Lesion Treatment Modalities: A Systematic Review

open access: yesANZ Journal of Surgery, EarlyView.
ABSTRACT Background There is compelling evidence that treating high‐grade squamous intraepithelial lesions (HSIL), the anal squamous cell cancer (ASCC) precursor, reduces the risk of developing ASCC. Using high‐resolution anoscopy (HRA), surgical excision, ablative and topical therapies are widely used to treat HSIL.
Matthew Joseph Marino   +5 more
wiley   +1 more source

Magnetic Resonance Imaging Evaluation of Functional Differences Between In Vivo Human Kidneys and Discarded Human Kidneys During Ex Vivo Normothermic Machine Perfusion

open access: yesArtificial Organs, EarlyView.
Comparative MRI of in vivo kidneys and ex vivo donor kidneys during NMP revealed marked physiological differences and limited correspondence with conventional perfusion or injury metrics. These distinct ex vivo MRI signatures emphasize the need to consider parameters beyond conventional in vivo functional markers when assessing organ viability during ...
Tim L. Hamelink   +12 more
wiley   +1 more source

When serology misleads: cross-reactivity in acute hepatitis. [PDF]

open access: yesArch Virol
Nowak K   +5 more
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz   +17 more
wiley   +1 more source

Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity. [PDF]

open access: yesInfect Dis Rep
Medeiros CMDS   +4 more
europepmc   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy